{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:26:41Z","timestamp":1761488801211},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.psc.2011.08.013","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T17:28:44Z","timestamp":1321550924000},"page":"871-880","source":"Crossref","is-referenced-by-count":8,"title":["Drug Treatment of Obesity"],"prefix":"10.1016","volume":"34","author":[{"given":"George A.","family":"Bray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna H.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psc.2011.08.013_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.2009.2014","article-title":"Prevalence and trends in obesity among US adults, 1999\u20132008","volume":"303","author":"Flegal","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.psc.2011.08.013_bib2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jama.2009.2012","article-title":"Prevalence of high body mass index in US children and adolescents, 2007\u20132008","volume":"303","author":"Ogden","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.psc.2011.08.013_bib3","series-title":"A guide to obesity and the metabolic syndrome: origins and treatment","author":"Bray","year":"2011"},{"key":"10.1016\/j.psc.2011.08.013_bib4","series-title":"The low-fructose approach to weight control","author":"Bray","year":"2009"},{"key":"10.1016\/j.psc.2011.08.013_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1124\/pr.59.2.2","article-title":"Pharmacological treatment of the overweight patient","volume":"59","author":"Bray","year":"2007","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.psc.2011.08.013_bib6","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1210\/en.2007-1321","article-title":"Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors","volume":"40","author":"Lam","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.psc.2011.08.013_bib7","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/oby.2009.69","article-title":"How physician obesity specialists use drugs to treat obesity","volume":"17","author":"Hendricks","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.psc.2011.08.013_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.psc.2011.08.013_bib9","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","article-title":"Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial","volume":"293","author":"Chanoine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.psc.2011.08.013_bib10","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","article-title":"Long term pharmacotherapy for obesity and overweight: updated meta-analysis","volume":"335","author":"Rucker","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.psc.2011.08.013_bib12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-142-7-200504050-00011","article-title":"Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians","volume":"142","author":"Snow","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.psc.2011.08.013_bib13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2009.03.016","article-title":"Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein","volume":"137","author":"He","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.psc.2011.08.013_bib14","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/S0149-2918(03)90089-0","article-title":"Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy","volume":"25","author":"Setter","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.psc.2011.08.013_bib15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/ncpendmet0843","article-title":"The prevention of type 2 diabetes","volume":"4","author":"Crandall","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.psc.2011.08.013_bib16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bmj.39063.689375.55","article-title":"Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis","volume":"334","author":"Gillies","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.psc.2011.08.013_bib17","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2337\/dc09-0258","article-title":"Metformin for obesity in children and adolescents: a systematic review","volume":"32","author":"Park","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.psc.2011.08.013_bib18","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/diacare.19.9.920","article-title":"The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution","volume":"19","author":"Fontbonne","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.psc.2011.08.013_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.diabet.2009.03.005","article-title":"Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial","volume":"35","author":"Fontbonne","year":"2009","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.psc.2011.08.013_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8210","article-title":"Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement","volume":"8","author":"Avenell","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.psc.2011.08.013_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.psc.2011.08.013_bib22","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.psc.2011.08.013_bib23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/j.1742-1241.2009.02224.x","article-title":"Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development?","volume":"63","author":"Bushe","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.psc.2011.08.013_bib24","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","article-title":"Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial","volume":"282","author":"Heymsfield","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.psc.2011.08.013_bib25","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/oby.2009.184","article-title":"Enhanced weight loss with pramlintide\/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy","volume":"17","author":"Ravussin","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.psc.2011.08.013_bib26","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.psc.2011.08.013_bib27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.psc.2011.08.013_bib28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.psc.2011.08.013_bib29","doi-asserted-by":"crossref","first-page":"468.e9","DOI":"10.1016\/j.amjmed.2009.11.019","article-title":"Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes","volume":"123","author":"Apovian","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.psc.2011.08.013_bib30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/dmrr.499","article-title":"Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes","volume":"20","author":"Fineman","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.psc.2011.08.013_bib31","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.psc.2011.08.013_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.psc.2011.08.013_bib33","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/oby.2001.71","article-title":"Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women","volume":"9","author":"Gadde","year":"2001","journal-title":"Obes Res"},{"key":"10.1016\/j.psc.2011.08.013_bib34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/oby.2002.86","article-title":"Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial","volume":"10","author":"Anderson","year":"2002","journal-title":"Obes Res"},{"key":"10.1016\/j.psc.2011.08.013_bib35","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity","volume":"11","author":"Bray","year":"2003","journal-title":"Obes Res"},{"key":"10.1016\/j.psc.2011.08.013_bib36","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.psc.2011.08.013_bib37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity","volume":"17","author":"Greenway","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.psc.2011.08.013_bib38","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X1100092X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X1100092X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T18:51:15Z","timestamp":1560970275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X1100092X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0193953X1100092X"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2011.08.013","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}